Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

iCAD finds partner for CT (computed tomography) lung CAD in development:

This article was originally published in Clinica

Executive Summary

Viatronix has agreed to distribute iCAD's new tool to help radiologists identify cancerous and precancerous lung nodules in computed tomography (CT) images. The technology is still in development and has yet to be approved by the FDA. Stony Brook, New York-based Viatronix sells 3D CT visualisation software. iCAD, of Nashua, New Hampshire, recently agreed to make film-based CAD mammography systems for partner Hologic to sell to clinics with low case volumes. The roll-out of the Second Look 200 system for low-volume practices drove third-quarter sales of $6m, compared with $1.6m a year earlier.

You may also be interested in...



RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.

 

 

FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

Topics

UsernamePublicRestriction

Register

MT060325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel